SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model
- 6 July 2010
- Vol. 28 (36), 5794-5802
- https://doi.org/10.1016/j.vaccine.2010.06.073
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicityVaccine, 2009
- Hypercostimulation through 4-1BB Distorts Homeostasis of Immune CellsThe Journal of Immunology, 2009
- Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel Form of 4-1BB Ligand Eradicates Established TumorsCancer Research, 2009
- Combined mobilization and stimulation of tumor‐infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL‐18 in vivo induces systemic antitumor immunityCancer Science, 2008
- Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanomaThe Journal of Experimental Medicine, 2008
- Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune EvasionCancer Research, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- NK and CD8+ T cell‐mediated eradication of poorly immunogenic B16‐F10 melanoma by the combined action of IL‐12 gene therapy and 4‐1BB costimulationInternational Journal of Cancer, 2004
- Biological activities and molecular targets of the human papillomavirus E7 oncoproteinOncogene, 2001
- Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteinsOncogene, 2000